Lipella Pharmaceuticals (LIPO) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for September 10, 2024, to be held virtually, with voting on key proposals including director elections, a reverse stock split, and auditor ratification.

• Record date for voting is August 1, 2024, with 8,004,636 shares of common stock outstanding and entitled to vote.

• Board recommends voting in favor of all proposals and director nominees.

Voting matters and shareholder proposals

• Election of seven directors to serve until the 2025 annual meeting.

• Authorization for the Board to effect a reverse stock split at a ratio between 1-for-5 and 1-for-150, at its discretion, within one year of approval.

• Ratification of Urish Popeck & Co., LLC as independent auditors for fiscal year 2024.

• No dissenter's rights for any proposal; other business may be transacted as appropriate.

Board of directors and corporate governance

• Board consists of seven members, with a majority deemed independent under Nasdaq rules.

• Board committees include audit, compensation, and nominating/governance, all composed of independent directors.

• Board diversity matrix provided; annual and ad-hoc meetings held, with full attendance at the 2023 annual meeting.

• No family relationships among officers or directors; CEO also serves as Chairman.